Jian Zhang1, Nong Yang2, Dongmei Ji1, Weina Shen1, Wenhua Li1, Rubing Han3, Ning Wang3, Haoxun Tao3, Sonya C Chapman4, Amanda K Sykes4, Wanli Zhang3, Xichun Hu5. 1. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 2. Department of Medical Oncology, Hunan Cancer Hospital, Changsha, China. 3. Eli Lilly and Company, Shanghai, China. 4. Eli Lilly and Company, Windlesham, UK. 5. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. xchu2009@hotmail.com.
Abstract
BACKGROUND:Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, is approved in combination with endocrine therapy or as monotherapy for hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) advanced breast cancer outside of China. OBJECTIVE: To evaluate the safety, tolerability, and pharmacokinetic (PK) profile of abemaciclib in Chinese patients with advanced and/or metastatic cancers. PATIENTS AND METHODS: A multicenter, open-label, phase I trial of abemaciclib in Chinese patients with advanced and/or metastatic cancers was conducted. Patients were randomized (1:1) to oral abemaciclib 150 or 200 mg every 12 h on a 28-day cycle. Safety analyses (primary outcome) included all patients receiving at least one dose of abemaciclib. PK and antitumor activity were also assessed. RESULTS: Of the 26 patients randomized, 25 received abemaciclib 150 mg (n = 12) or 200 mg (n = 13). All 25 patients reported ≥ 1 treatment-emergent adverse event (TEAE). The majority of TEAEs were Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or 2 in severity. The most frequent TEAEs of Grade ≥ 3 were neutropenia (32%) and thrombocytopenia (24%). Four patients (16%) discontinued treatment due to AEs. Abemaciclib exhibited slow absorption and clearance at single dose, with maximum concentrations achieved after around 6 h and an elimination half-life of approximately 24 h. No complete response was observed, two patients (8%) achieved partial response, with one confirmed responder, and the disease control rate was 68% (n = 17). CONCLUSIONS:Abemaciclib was well tolerated and the safety and PK profiles in Chinese patients were comparable to those previously reported in non-Chinese populations. Preliminary antitumor activity was observed. CLINICALTRIALS. GOV IDENTIFIER: NCT02919696.
RCT Entities:
BACKGROUND:Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, is approved in combination with endocrine therapy or as monotherapy for hormone receptor-positive and humanepidermal growth factor receptor-2-negative (HR+/HER2-) advanced breast cancer outside of China. OBJECTIVE: To evaluate the safety, tolerability, and pharmacokinetic (PK) profile of abemaciclib in Chinese patients with advanced and/or metastatic cancers. PATIENTS AND METHODS: A multicenter, open-label, phase I trial of abemaciclib in Chinese patients with advanced and/or metastatic cancers was conducted. Patients were randomized (1:1) to oral abemaciclib 150 or 200 mg every 12 h on a 28-day cycle. Safety analyses (primary outcome) included all patients receiving at least one dose of abemaciclib. PK and antitumor activity were also assessed. RESULTS: Of the 26 patients randomized, 25 received abemaciclib 150 mg (n = 12) or 200 mg (n = 13). All 25 patients reported ≥ 1 treatment-emergent adverse event (TEAE). The majority of TEAEs were Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or 2 in severity. The most frequent TEAEs of Grade ≥ 3 were neutropenia (32%) and thrombocytopenia (24%). Four patients (16%) discontinued treatment due to AEs. Abemaciclib exhibited slow absorption and clearance at single dose, with maximum concentrations achieved after around 6 h and an elimination half-life of approximately 24 h. No complete response was observed, two patients (8%) achieved partial response, with one confirmed responder, and the disease control rate was 68% (n = 17). CONCLUSIONS:Abemaciclib was well tolerated and the safety and PK profiles in Chinese patients were comparable to those previously reported in non-Chinese populations. Preliminary antitumor activity was observed. CLINICALTRIALS. GOV IDENTIFIER: NCT02919696.
Authors: Maura N Dickler; Sara M Tolaney; Hope S Rugo; Javier Cortés; Véronique Diéras; Debra Patt; Hans Wildiers; Clifford A Hudis; Joyce O'Shaughnessy; Esther Zamora; Denise A Yardley; Martin Frenzel; Andrew Koustenis; José Baselga Journal: Clin Cancer Res Date: 2017-05-22 Impact factor: 12.531
Authors: George W Sledge; Masakazu Toi; Patrick Neven; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; Martin Frenzel; Yong Lin; Susana Barriga; Ian C Smith; Nawel Bourayou; Antonio Llombart-Cussac Journal: J Clin Oncol Date: 2017-06-03 Impact factor: 44.544
Authors: Matthew P Goetz; Masakazu Toi; Mario Campone; Joohyuk Sohn; Shani Paluch-Shimon; Jens Huober; In Hae Park; Olivier Trédan; Shin-Cheh Chen; Luis Manso; Orit C Freedman; Georgina Garnica Jaliffe; Tammy Forrester; Martin Frenzel; Susana Barriga; Ian C Smith; Nawel Bourayou; Angelo Di Leo Journal: J Clin Oncol Date: 2017-10-02 Impact factor: 44.544
Authors: Amita Patnaik; Lee S Rosen; Sara M Tolaney; Anthony W Tolcher; Jonathan W Goldman; Leena Gandhi; Kyriakos P Papadopoulos; Muralidhar Beeram; Drew W Rasco; John F Hilton; Aejaz Nasir; Richard P Beckmann; Andrew E Schade; Angie D Fulford; Tuan S Nguyen; Ricardo Martinez; Palaniappan Kulanthaivel; Lily Q Li; Martin Frenzel; Damien M Cronier; Edward M Chan; Keith T Flaherty; Patrick Y Wen; Geoffrey I Shapiro Journal: Cancer Discov Date: 2016-05-23 Impact factor: 39.397
Authors: Lawrence M Gelbert; Shufen Cai; Xi Lin; Concepcion Sanchez-Martinez; Miriam Del Prado; Maria Jose Lallena; Raquel Torres; Rose T Ajamie; Graham N Wishart; Robert Steven Flack; Blake Lee Neubauer; Jamie Young; Edward M Chan; Philip Iversen; Damien Cronier; Emiko Kreklau; Alfonso de Dios Journal: Invest New Drugs Date: 2014-06-13 Impact factor: 3.850
Authors: Raquel Torres-Guzmán; Bruna Calsina; Ana Hermoso; Carmen Baquero; Beatriz Alvarez; Joaquín Amat; Ann M McNulty; Xueqian Gong; Karsten Boehnke; Jian Du; Alfonso de Dios; Richard P Beckmann; Sean Buchanan; María José Lallena Journal: Oncotarget Date: 2017-05-10